Recent Posts on This Topic | See All >
TGen and TD2 help Critical Outcome Technologies to present data at US Oncology summitTags: cancer, tgen
[Source: TGen] - Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) is pleased to announce that it has accepted an invitation from US Oncology to present at the US Oncology Translational Oncology Program (TOP) Science Summit in Houston, Texas, on March 27, 2010.
The TOP science summit is a collaborative forum of scientific and academic thought leaders in early phase oncology research who assemble at this annual event to discuss new trends in oncology drug development and learn about promising investigational cancer compounds entering development.
Now available: “Arizona’s Bioscience Roadmap 2014-2025: Advancing the Biosciences and Improving Health Outcomes,” is now available along with its supplement, “Summary of Goals, Strategies, and Potential Actions.” An overview by Walter Plosila, Ph.D., Battelle senior advisor, is also available. The updated Roadmap provides a long-term strategy for Arizona to achieve bioscience success over the next decade.